Status:

ACTIVE_NOT_RECRUITING

Analysis of Liver Injury Risk Factors in a Multiethnic Population Treated With Antituberculosis Drugs

Lead Sponsor:

Stefania Cheli

Conditions:

Tuberculosis Infection

Eligibility:

All Genders

18+ years

Brief Summary

Tuberculosis (TB) is the world's second leading cause of death from a single infectious agent after COVID-19. In 2022, TB was estimated to have affected 10.6 million people, of whom 1.3 million died b...

Detailed Description

Tuberculosis (TB) is the world's second leading cause of death from a single infectious agent in 2022, after COVID-19. In 2022, TB disease was estimated to affect 10.6 million people, of whom 1.3 mill...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • adult patients (\>18 years)
  • patient who received standard initial therapy including INH (5mg/kg), RMP (10mg/kg), and PZA (25mg/kg) for patients with active TB disease
  • treatment with first line anti-TB drugs, including rifampicin and isoniazid for patients with latent TBI
  • normal serum ALT and bilirubin levels, no symptoms related to abnormal liver function prior to anti-TB drug treatment
  • informed consent.
  • Exclusion criteria:
  • liver dysfunction, including biliary origin, before anti-TB therapy
  • patients receiving non-standard treatment regimen initially (e.g., patients with severe pulmonary or extrapulmonary TB receiving large doses or more than four anti-TB drugs), 3) modified treatment regimen due to drug resistance or intolerance excluding first line anti-TB drugs
  • 4\) lactation or pregnancy 5) concomitant use of hepatotoxic drugs 6) abnormal hepatic function on laboratory testing before anti-TB 7) disease that was resistant to INH at the start of treatment 8) patients refusing to sign informed consent.

Exclusion

    Key Trial Info

    Start Date :

    July 5 2024

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    September 30 2024

    Estimated Enrollment :

    127 Patients enrolled

    Trial Details

    Trial ID

    NCT06539455

    Start Date

    July 5 2024

    End Date

    September 30 2024

    Last Update

    August 6 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    ASST Fatebenefratelli Sacco

    Milan, Italy, 20157